Cargando…

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Myeloma bone disease is a major complication in multiple myeloma affecting quality of life and survival. It is characterized by increased activity of osteoclasts, bone resorbing cells. Myeloma microenvironment promotes excessive osteoclastogenesis, a process of production of osteoclasts from their p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Byrgazov, Konstantin, Lind, Thomas, Rasmusson, Annica J., Andersson, Claes, Slipicevic, Ana, Lehmann, Fredrik, Gullbo, Joachim, Melhus, Håkan, Larsson, Rolf, Fryknäs, Mårten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192817/ https://www.ncbi.nlm.nih.gov/pubmed/34150958 http://dx.doi.org/10.1016/j.bonr.2021.101098

Ejemplares similares

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
por: Byrgazov, Konstantin, et al.
Publicado: (2020)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma
por: Morabito, Fortunato, et al.
Publicado: (2021)

Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
por: Schjesvold, Fredrik H, et al.
Publicado: (2022)

Effects of hypoxia on human cancer cell line chemosensitivity
por: Strese, Sara, et al.
Publicado: (2013)

Excessive dietary intake of vitamin A reduces skull bone thickness in mice
por: Lind, Thomas, et al.
Publicado: (2017)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

Ex Vivo Activity of Cardiac Glycosides in Acute Leukaemia
por: Hallböök, Helene, et al.
Publicado: (2011)

A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation
por: Karlsson, Henning, et al.
Publicado: (2019)

Increased Bone Mass in Female Mice Lacking Mast Cell Chymase
por: Lind, Thomas, et al.
Publicado: (2016)

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
por: Fryknäs, Mårten, et al.
Publicado: (2013)

Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
por: Selvin, Tove, et al.
Publicado: (2022)

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
por: Andersson, Claes R., et al.
Publicado: (2022)

The Free Hormone Hypothesis: Is Free Serum 25‐Hydroxyvitamin D a Better Marker for Bone Mineral Density in Older Women?
por: Michaëlsson, Karl, et al.
Publicado: (2018)

Mechanistic characterization of a copper containing thiosemicarbazone with potent antitumor activity
por: Karlsson, Henning, et al.
Publicado: (2017)

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
por: Selvin, Tove, et al.
Publicado: (2023)

Vitamin A Is a Negative Regulator of Osteoblast Mineralization
por: Lind, Thomas, et al.
Publicado: (2013)

Retinoic Acid Increases Proliferation of Human Osteoclast Progenitors and Inhibits RANKL-Stimulated Osteoclast Differentiation by Suppressing RANK
por: Hu, Lijuan, et al.
Publicado: (2010)

Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients
por: Johansson, Junko, et al.
Publicado: (2018)

Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
por: Nygren, Peter, et al.
Publicado: (2013)

Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing
por: Rubin, Jenny, et al.
Publicado: (2018)

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
por: Blom, Kristin, et al.
Publicado: (2019)

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
por: Ek, Frida, et al.
Publicado: (2022)

Selective radiosensitization by nitazoxanide of quiescent clonogenic colon cancer tumour cells
por: Karlsson, Henning, et al.
Publicado: (2022)

Can mutations in ELA2, neutrophil elastase expression or differential cell toxicity explain sulphasalazine-induced agranulocytosis?
por: Jacobson, Annica, et al.
Publicado: (2004)

Iron chelators target both proliferating and quiescent cancer cells
por: Fryknäs, Mårten, et al.
Publicado: (2016)

Mebendazole is unique among tubulin-active drugs in activating the MEK–ERK pathway
por: Andersson, Claes R., et al.
Publicado: (2020)

Identification of a Novel Topoisomerase Inhibitor Effective in Cells Overexpressing Drug Efflux Transporters
por: Fayad, Walid, et al.
Publicado: (2009)

Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia
por: Eriksson, A, et al.
Publicado: (2015)

Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles
por: Rickardson, L, et al.
Publicado: (2005)

Immobilization of Denosumab on Titanium Affects Osteoclastogenesis of Human Peripheral Blood Monocytes
por: Beck, Felicitas, et al.
Publicado: (2019)

Effects of adiponectin on osteoclastogenesis from mouse bone marrow-derived monocytes
por: Wu, Xia, et al.
Publicado: (2019)

Osteoclastogenesis of human peripheral blood, bone marrow, and cord blood monocytes
por: Vuoti, Ella, et al.
Publicado: (2023)

Studies of indirect and direct effects of hypervitaminosis A on rat bone by comparing free access to food and pair-feeding
por: Lind, Thomas, et al.
Publicado: (2018)

Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells
por: Milani, Lili, et al.
Publicado: (2007)

Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments
por: Zhang, Xiaonan, et al.
Publicado: (2014)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Melflufen - a peptidase-potentiated alkylating agent in clinical trials
por: Wickström, Malin, et al.
Publicado: (2017)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Multidrug resistance protein-mediated transport of chlorambucil and melphalan conjugated to glutathione.
por: Barnouin, K., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_fc7b8n78ruf01kse31se5j2oea